Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer

Introduction Tyrosine kinase inhibitors (TKIs) have significantly improved the progression-free survival (PFS) of metastatic non-small cell lung cancer (NSCLC) with oncogene mutations of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) compared with systemic therapy alone...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sadhna Kannan, Kumar Prabhash, Anil Tibdewal, JaiPrakash Agarwal, Naveen Mummudi, Vanita Noronha, Vijay Patil, Nilendu Purandare, Amit Janu, Rajiv Kaushal
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/92f32865e1284db5868d83e018827764
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:92f32865e1284db5868d83e018827764
record_format	dspace
spelling	oai:doaj.org-article:92f32865e1284db5868d83e0188277642021-11-19T14:30:05ZProtocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer10.1136/bmjopen-2020-0413452044-6055https://doaj.org/article/92f32865e1284db5868d83e0188277642021-02-01T00:00:00Zhttps://bmjopen.bmj.com/content/11/2/e041345.fullhttps://doaj.org/toc/2044-6055Introduction Tyrosine kinase inhibitors (TKIs) have significantly improved the progression-free survival (PFS) of metastatic non-small cell lung cancer (NSCLC) with oncogene mutations of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) compared with systemic therapy alone. However, the majority eventually develop resistance with a median PFS of 8–12 months. The pattern of failure studies showed disease relapse at the original sites of the disease-harbouring resistant tumour cells.Methods and analysis This study is designed as a phase II randomised controlled trial to evaluate the efficacy of local consolidative radiation therapy (LCRT) in addition to TKI in upfront oligometastatic NSCLC. Patients will be screened at presentation for oligometastases (≤5 sites) and will start on TKI after confirmation of EGFR or ALK mutation status. After initial TKI for 2–4 months, eligible patients will be randomised in a 1:1 ratio with stratification of oligometastatic sites (1–3 vs 4–5), performance status of 0–1 versus 2 and brain metastases. The standard arm will continue to receive TKI, and the intervention arm will receive TKI plus LCRT. Stereotactic body radiation therapy will be delivered to all the oligometastatic sites.The primary end point is PFS, and secondary end points are overall survival, local control of oligometastatic sites, toxicity and patient-reported outcomes. The sample size calculation took a median PFS of 10 months in the standard arm. To detect an absolute improvement of 7 months in the interventional arm, with a one-sided alpha of 5% and 80% power, a total of 106 patients will be accrued over a period of 48 months.Ethics and dissemination The study is approved by the Institutional Ethics Committee II of Tata Memorial Centre, Mumbai, and registered with Clinical Trials Registry—India, CTRI/2019/11/021872, dated 5 November 2019. All eligible participants will be provided with a participant information sheet and will be required to provide written informed consent for participation in the study. The study results will be presented at a national/international conference and will be published in a peer-reviewed journal.Sadhna KannanKumar PrabhashAnil TibdewalJaiPrakash AgarwalNaveen MummudiVanita NoronhaVijay PatilNilendu PurandareAmit JanuRajiv KaushalBMJ Publishing GrouparticleMedicineRENBMJ Open, Vol 11, Iss 2 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R
spellingShingle	Medicine R Sadhna Kannan Kumar Prabhash Anil Tibdewal JaiPrakash Agarwal Naveen Mummudi Vanita Noronha Vijay Patil Nilendu Purandare Amit Janu Rajiv Kaushal Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer
description	Introduction Tyrosine kinase inhibitors (TKIs) have significantly improved the progression-free survival (PFS) of metastatic non-small cell lung cancer (NSCLC) with oncogene mutations of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) compared with systemic therapy alone. However, the majority eventually develop resistance with a median PFS of 8–12 months. The pattern of failure studies showed disease relapse at the original sites of the disease-harbouring resistant tumour cells.Methods and analysis This study is designed as a phase II randomised controlled trial to evaluate the efficacy of local consolidative radiation therapy (LCRT) in addition to TKI in upfront oligometastatic NSCLC. Patients will be screened at presentation for oligometastases (≤5 sites) and will start on TKI after confirmation of EGFR or ALK mutation status. After initial TKI for 2–4 months, eligible patients will be randomised in a 1:1 ratio with stratification of oligometastatic sites (1–3 vs 4–5), performance status of 0–1 versus 2 and brain metastases. The standard arm will continue to receive TKI, and the intervention arm will receive TKI plus LCRT. Stereotactic body radiation therapy will be delivered to all the oligometastatic sites.The primary end point is PFS, and secondary end points are overall survival, local control of oligometastatic sites, toxicity and patient-reported outcomes. The sample size calculation took a median PFS of 10 months in the standard arm. To detect an absolute improvement of 7 months in the interventional arm, with a one-sided alpha of 5% and 80% power, a total of 106 patients will be accrued over a period of 48 months.Ethics and dissemination The study is approved by the Institutional Ethics Committee II of Tata Memorial Centre, Mumbai, and registered with Clinical Trials Registry—India, CTRI/2019/11/021872, dated 5 November 2019. All eligible participants will be provided with a participant information sheet and will be required to provide written informed consent for participation in the study. The study results will be presented at a national/international conference and will be published in a peer-reviewed journal.
format	article
author	Sadhna Kannan Kumar Prabhash Anil Tibdewal JaiPrakash Agarwal Naveen Mummudi Vanita Noronha Vijay Patil Nilendu Purandare Amit Janu Rajiv Kaushal
author_facet	Sadhna Kannan Kumar Prabhash Anil Tibdewal JaiPrakash Agarwal Naveen Mummudi Vanita Noronha Vijay Patil Nilendu Purandare Amit Janu Rajiv Kaushal
author_sort	Sadhna Kannan
title	Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer
title_short	Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer
title_full	Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer
title_fullStr	Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer
title_full_unstemmed	Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer
title_sort	protocol for a phase ii randomised controlled trial of tki alone versus tki and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer
publisher	BMJ Publishing Group
publishDate	2021
url	https://doaj.org/article/92f32865e1284db5868d83e018827764
work_keys_str_mv	AT sadhnakannan protocolforaphaseiirandomisedcontrolledtrialoftkialoneversustkiandlocalconsolidativeradiationtherapyinpatientswithoncogenedrivermutatedoligometastaticnonsmallcelllungcancer AT kumarprabhash protocolforaphaseiirandomisedcontrolledtrialoftkialoneversustkiandlocalconsolidativeradiationtherapyinpatientswithoncogenedrivermutatedoligometastaticnonsmallcelllungcancer AT aniltibdewal protocolforaphaseiirandomisedcontrolledtrialoftkialoneversustkiandlocalconsolidativeradiationtherapyinpatientswithoncogenedrivermutatedoligometastaticnonsmallcelllungcancer AT jaiprakashagarwal protocolforaphaseiirandomisedcontrolledtrialoftkialoneversustkiandlocalconsolidativeradiationtherapyinpatientswithoncogenedrivermutatedoligometastaticnonsmallcelllungcancer AT naveenmummudi protocolforaphaseiirandomisedcontrolledtrialoftkialoneversustkiandlocalconsolidativeradiationtherapyinpatientswithoncogenedrivermutatedoligometastaticnonsmallcelllungcancer AT vanitanoronha protocolforaphaseiirandomisedcontrolledtrialoftkialoneversustkiandlocalconsolidativeradiationtherapyinpatientswithoncogenedrivermutatedoligometastaticnonsmallcelllungcancer AT vijaypatil protocolforaphaseiirandomisedcontrolledtrialoftkialoneversustkiandlocalconsolidativeradiationtherapyinpatientswithoncogenedrivermutatedoligometastaticnonsmallcelllungcancer AT nilendupurandare protocolforaphaseiirandomisedcontrolledtrialoftkialoneversustkiandlocalconsolidativeradiationtherapyinpatientswithoncogenedrivermutatedoligometastaticnonsmallcelllungcancer AT amitjanu protocolforaphaseiirandomisedcontrolledtrialoftkialoneversustkiandlocalconsolidativeradiationtherapyinpatientswithoncogenedrivermutatedoligometastaticnonsmallcelllungcancer AT rajivkaushal protocolforaphaseiirandomisedcontrolledtrialoftkialoneversustkiandlocalconsolidativeradiationtherapyinpatientswithoncogenedrivermutatedoligometastaticnonsmallcelllungcancer
_version_	1718420084251164672

Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer

Ejemplares similares